CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company’s pacritinib development program in graft versus host disease (GVHD) at the 62 nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020 . The details of the presentation are as follow
| SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company’s pacritinib development program in graft versus host disease (GVHD) at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, being held virtually December 5- 8, 2020. The details of the presentation are as follows: Abstract Title: Biological and Clinical Impact of JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I Trial Results A copy of the abstract is available here. About CTI BioPharma Corp. We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington. CTI BioPharma Investor Contacts: Maeve Conneighton/Maghan Meyers
SOURCE CTI BioPharma Corp. | ||
Company Codes: NASDAQ-SMALL:CTIC |
View original content to download multimedia:
